Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more
Advanced Biomed Inc. Common Stock (ADVB) - Total Assets
Latest total assets as of December 2025: $10.85 Million USD
Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) holds total assets worth $10.85 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Advanced Biomed Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Advanced Biomed Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
Advanced Biomed Inc. Common Stock's total assets of $10.85 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.6% |
| Accounts Receivable | $7.96K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advanced Biomed Inc. Common Stock's current assets represent 92.6% of total assets in 2025, an increase from 90.8% in 2021.
- Cash Position: Cash and equivalents constituted 44.6% of total assets in 2025, up from 6.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Advanced Biomed Inc. Common Stock Competitors by Total Assets
Key competitors of Advanced Biomed Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Advanced Biomed Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Advanced Biomed Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Advanced Biomed Inc. Common Stock is currently not profitable relative to its asset base.
Advanced Biomed Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.56 | 0.82 | 1.67 |
| Quick Ratio | 8.55 | 0.82 | 1.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.48 Million | $ -689.90K | $ 2.02 Million |
Advanced Biomed Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Advanced Biomed Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 145908.6% |
| Total Assets | $6.51 Billion |
| Market Capitalization | $1.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Advanced Biomed Inc. Common Stock's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Advanced Biomed Inc. Common Stock's assets grew by 145908.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Advanced Biomed Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $6.51 Billion | +145908.57% |
| 2024-06-30 | $4.46 Million | -3.04% |
| 2023-06-30 | $4.60 Million | -31.48% |
| 2022-06-30 | $6.71 Million | +567.10% |
| 2021-06-30 | $1.01 Million | -- |